Quviviq (daridorexant) received FDA approval on January 10, 2022 [1]. The drug is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1][2].
How does Quviviq work to help with insomnia?
Quviviq is a dual orexin receptor antagonist. It works by blocking the activity of orexin, a neuropeptide that promotes wakefulness. By inhibiting orexin signaling, Quviviq reduces the stimulation of wakefulness pathways, thereby facilitating sleep onset and maintenance [1][2][3].
What is the recommended dosage for Quviviq?
The recommended dosage for Quviviq is 25 mg or 50 mg taken orally once nightly [1]. It should be taken no more than 30 minutes before bedtime and only when a patient is able to stay asleep for at least 7 hours [2].
What are the potential side effects of Quviviq?
The most common side effects reported in clinical trials for Quviviq included somnolence (drowsiness), headache, and fatigue [1][2]. Some patients may experience dizziness or nausea [2]. Because Quviviq can cause drowsiness, it is important for patients to avoid driving or engaging in other dangerous activities until they know how the medication affects them [2].
When does Quviviq's patent expire?
Information regarding the specific patent expiry dates for Quviviq is available through resources like DrugPatentWatch.com [4]. Patents for new drugs are typically granted for 20 years from the filing date, but various factors can affect the actual market exclusivity period [4].
How does Quviviq compare to other insomnia medications?
Quviviq represents a different class of insomnia medication compared to older drugs like benzodiazepines or Z-drugs. As a dual orexin receptor antagonist, it targets the wakefulness system rather than acting as a general sedative [1][3]. This mechanism may offer a different side effect profile for some patients.
What are the risks associated with Quviviq?
Quviviq carries a risk of central nervous system depression, which can lead to drowsiness and impaired driving ability [2]. There is also a risk of complex sleep behaviors, such as sleepwalking or sleep-driving, although these are rare [2]. Patients with narcolepsy should not take Quviviq as it can worsen their condition [2].
Can Quviviq be prescribed to everyone with insomnia?
Quviviq is not intended for long-term use and has not been studied for more than 12 months [1]. It is also not recommended for patients with severe liver impairment [2]. A healthcare provider will determine if Quviviq is an appropriate treatment option based on an individual's medical history and specific insomnia symptoms [1][2].
---
Sources
1. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-letter-2022
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215824s000lbl.pdf
3. https://www.drugpatentwatch.com/drug/quviviq/
4. https://www.drugpatentwatch.com/